US EditionOvarian cancer immunotherapy boosts immune response in trial
Summary by rarecancernews.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Ovarian cancer immunotherapy boosts immune response in trial
IMNN-001, Imunon’s experimental immunotherapy for advanced ovarian cancer, boosts the body’s natural immune response by increasing levels of immune signaling proteins that aid in attacking tumors, new clinical data show. These results, from the Phase 1/2 OVATION 2 trial (NCT03393884), help explain how the treatment may be working at a molecular level, according to the U.S.-based developer. The data also support earlier findings from the ongoing …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
